The effects of piracetam in children with dyslexia. 1985

M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta

Following previous research which suggests that piracetam improves performance on tasks associated with the left hemisphere, a 12-week, double-blind, placebo-controlled study of developmental dyslexics was conducted. Six study sites treated 257 dyslexic boys between the ages of 8 and 13 years who were significantly below their potential in reading performance. Children were of at least normal intelligence, had normal findings on audiologic, ophthalmologic, neurologic, and physical examination, and were neither educationally deprived nor emotionally disturbed. Piracetam was found to be well tolerated in this study population. Children treated with piracetam showed improvements in reading speed. No other effects on reading were observed. In addition, improvement in auditory sequential short-term memory was observed in those piracetam-treated patients who showed relatively poor memory at baseline. It is suggested that longer term treatment with piracetam may result in additional improvements.

UI MeSH Term Description Entries
D008297 Male Males
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D008570 Memory, Short-Term Remembrance of information for a few seconds to hours. Immediate Recall,Memory, Immediate,Working Memory,Memory, Shortterm,Immediate Memories,Immediate Memory,Immediate Recalls,Memories, Immediate,Memories, Short-Term,Memories, Shortterm,Memory, Short Term,Recall, Immediate,Recalls, Immediate,Short-Term Memories,Short-Term Memory,Shortterm Memories,Shortterm Memory,Working Memories
D010889 Piracetam A compound suggested to be both a nootropic and a neuroprotective agent. 2-Pyrrolidone-N-Acetamide,Avigilen,Axonyl,Cerebroforte,Cerepar N,Ciclofalina,Cuxabrain,Dinagen,Gabacet,Geram,Memo-Puren,Nootrop,Nootropil,Nootropyl,Normabraïn,Piracebral,Piracetam AbZ,Piracetam-RPh,Piracetrop,Pirazetam,Pyracetam,Pyramem,Sinapsan,UCB-6215,Memo Puren,Piracetam RPh,UCB 6215,UCB6215
D011760 Pyrrolidinones A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed) Pyrrolidinone,Pyrrolidone,Pyrrolidones
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D004410 Dyslexia A cognitive disorder characterized by an impaired ability to comprehend written and printed words or phrases despite intact vision. This condition may be developmental or acquired. Developmental dyslexia is marked by reading achievement that falls substantially below that expected given the individual's chronological age, measured intelligence, and age-appropriate education. The disturbance in reading significantly interferes with academic achievement or with activities of daily living that require reading skills. (From DSM-IV) Alexia,Dyslexia, Developmental,Reading Disability, Developmental,Reading Disorder,Reading Disorder, Developmental,Developmental Reading Disorder,Word Blindness,Alexias,Blindness, Word,Blindnesses, Word,Developmental Dyslexia,Developmental Dyslexias,Developmental Reading Disabilities,Developmental Reading Disability,Developmental Reading Disorders,Disabilities, Developmental Reading,Disability, Developmental Reading,Disorder, Developmental Reading,Disorder, Reading,Disorders, Developmental Reading,Disorders, Reading,Dyslexias,Dyslexias, Developmental,Reading Disabilities, Developmental,Reading Disorders,Reading Disorders, Developmental,Word Blindnesses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta
May 1986, International journal of psychophysiology : official journal of the International Organization of Psychophysiology,
M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta
August 1987, Journal of clinical psychopharmacology,
M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta
January 1984, Annals of dyslexia,
M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta
July 1980, Psychopharmacology bulletin,
M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta
January 1987, Journal of psychopharmacology (Oxford, England),
M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta
September 1979, Psychopharmacology,
M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta
October 2020, The Journal of the Acoustical Society of America,
M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta
November 1991, Journal of learning disabilities,
M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta
May 2018, Dyslexia (Chichester, England),
M Di Ianni, and C R Wilsher, and M S Blank, and C K Conners, and C H Chase, and H H Funkenstein, and E Helfgott, and J M Holmes, and L Lougee, and G J Maletta
September 1987, Psychophysiology,
Copied contents to your clipboard!